Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang – 7 April 2018 – Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV‐related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines.

Edward Yang, Lan Peng, William M. Lee – 6 April 2018

Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Patrick R. Varley, Julie Goswami, Hamza O. Yazdani, Samer Tohme, Patricia Loughran, Robert M. O'Doherty, Marta I. Minervini, Hai Huang, Richard L. Simmons, Allan Tsung – 6 April 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver disease. It is the most rapidly rising risk factor for the development of hepatocellular carcinoma (HCC), which can arise in NASH with or without cirrhosis. The inflammatory signals promoting the progression of NASH to HCC remain largely unknown.

Jonathan Nahas, Gene Y. Im – 6 April 2018

Samarth S. Patel, Mohammad Shadab Siddiqui – 6 April 2018

Tram T. Tran – 6 April 2018

Jorge A. Marrero, Laura M. Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michael M. Abecassis, Lewis R. Roberts, Julie K. Heimbach – 6 April 2018

Nazia Selzner, Marina Berenguer – 6 April 2018 – Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high‐quality liver grafts are much needed. Direct‐acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV‐positive donors into HCV‐negative recipients.

Nancy Reau – 6 April 2018

Jason Lewis – 6 April 2018